SeVeR: Selective Visual Exposure and Retrieval for 3D Medical Image Question Answering
Organizations: DAMO Academy, Alibaba Group · College of Computer Science and Technology, Zhejiang University · State Key Laboratory of Transvascular Implantation Devices and TIDRI, Zhejiang University · The Second Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine ·
Abstract
Volumetric medical VQA requires reasoning over long and redundant 3D visual token sequences, especially in multi-sequence MRI where complementary modalities provide diverse diagnostic cues but expose the decoder to many repeated anatomical regions. To investigate reasoning under multi-sequence visual redundancy, we first introduce BreMRIs-VQA, a clinically curated breast MRI benchmark with 1.19M QA pairs from 71.0K sequences and 12.9K patients, covering both free-text and multiple-choice questions. We further propose SeVeR, a selective visual exposure framework that compresses dense volumes into modality-wise prototypes and retrieves complementary multi-level evidence with change-aware gated attention during decoding, trained with a marginal-utility self-consistency objective that suppresses unhelpful retrieval. Experiments on BreMRIs-VQA and public benchmarks show that SeVeR improves both discriminative and generative performance while exposing substantially fewer visual tokens.
Figures & tables
| Task | Metric | Zero-shot | Fine-tune | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Qwen3-VL | Hulu-Med | Hulu-Med | Lingshu | M3D-Phi3 | M3D-L2 | M3D-L3 | Lingshu | Qwen3-VL | SeVeR | ||
| 4B | 4B | 7B | 32B | 4B | 7B | 8B | 7B | 4B | 4B | ||
| Global Background Assessment | Accuracy | 23.20 | 57.25 | 59.95 | 69.43 | 76.78 | 72.83 | 66.53 | 88.23 | 89.43 | 89.82 |
| BLEU | 72.76 | 80.34 | 82.91 | 85.12 | 91.23 | 92.87 | 90.12 | 95.92 | 96.55 | 96.63 | |
| ROUGE | 72.63 | 84.76 | 87.42 | 91.07 | 93.45 | 94.81 | 92.15 | 97.42 | 97.86 | 97.85 | |
| BERT. | 94.41 | 97.83 | 98.36 | 99.27 | 98.94 | 99.22 | 98.83 | 99.62 | 99.63 | 99.68 | |
| Method | Vis. Tokens | Lat. (ms) | Accuracy | BERT. |
|---|---|---|---|---|
| Baseline | 12544 | 952.6 | 69.18 | 98.42 |
| VisionZip | 256 | 630.8 | 67.63 | 98.16 |
| VisionZip | 512 | 698.4 | 68.72 | 98.34 |
| VisionZip | 1024 | 829.6 | 69.03 | 98.39 |
| DivPrune | 256 | 605.7 | 67.21 | 98.08 |
| DivPrune | 512 | 625.6 | 68.24 | 98.25 |
| Task | Metric | Zero-shot | Finetune | |||||||||
| Q2.5VL | Q3VL | RadFM | M3D-L2 | M3D-P3 | OmniV | Lingshu | M3D-L2 | M3D-P3 | Qwen3-VL | SeVeR | ||
| 4B | 4B | 13B | 7B | 4B | 1.5B | 7B | 7B | 4B | 4B | 4B | ||
| Exist. Det. | Accuracy | 19.52 | 3.52 | 29.20 | 18.00 | 40.25 | 28.66 | 59.60 | 81.09 | 82.43 | 82.52 | 82.62 |
| Static T. Diag. | Accuracy | 0.00 | 0.00 | 44.11 | 25.47 | 25.40 | 22.96 | 6.02 | 51.20 | 49.30 | 47.70 | 51.77 |
| Longit. T. Diag. | Accuracy | 0.29 | 0.15 | 42.99 | 24.17 | 24.31 | 24.23 | 12.13 | 74.78 | 74.77 | 74.39 | 75.28 |
| Medical Measurement | BLEU | 1.78 | 0.11 | 3.34 | 15.95 | 2.55 | 2.52 | 2.50 | 30.54 | 33.52 | 35.01 | 36.78 |
| Type | Metric | Merlin | M3D-L2 | M3D-P3 | CT-CHAT | RadFM | SeVeR |
|---|---|---|---|---|---|---|---|
| Meas | MC | 0.256 | 0.733 | 0.740 | 0.740 | 0.739 | 0.735 |
| FT | 0.364 | 0.370 | 0.366 | 0.379 | 0.434 | 0.521 | |
| Recog | MC | 0.661 | 0.664 | 0.661 | 0.664 | 0.789 | 0.707 |
| FT | 0.664 | 0.665 | 0.660 | 0.663 | 0.812 | 0.715 | |
| VisRsn | MC | 0.382 | 0.616 | 0.627 | 0.620 | 0.625 | 0.673 |
| FT | 0.392 | 0.408 | 0.420 | 0.428 | 0.439 | 0.499 |
| Setting | Acc. | BLEU | ROUGE | BERT. | |
|---|---|---|---|---|---|
| Baseline Ft. | 69.45 | 89.87 | 89.56 | 98.58 | 4608 |
| w/o CaGA | 64.36 | 88.92 | 85.30 | 95.42 | 512 |
| w/o Regul. | 68.17 | 87.04 | 89.16 | 97.63 | 512 |
| Q-GPS | 69.92 | 90.21 | 89.83 | 97.66 | 512 |
| SeVeR | 70.57 | 91.08 | 90.15 | 98.70 | 512 |
Appendix figures & tables15 assets
Supplementary material from the paper’s appendix.
Appendix
| Category | Question Template | Options |
| Fibroglandular Tissue (FGT) | What is the fibroglandular tissue (FGT) category of the left breast? | A, B, C, D, None |
| What is the fibroglandular tissue (FGT) category of the right breast? | A, B, C, D, None | |
| Background Parenchymal Enhancement | What is the background parenchymal enhancement (BPE) level of the left breast? | Minimal, Mild, Moderate, Marked |
| What is the background parenchymal enhancement (BPE) level of the right breast? | Minimal, Mild, Moderate, Marked | |
| Breast Symmetry | Are the breasts symmetric in size and shape? | Yes, No |
| Post-surgical Changes | Are there evidence of scar tissue in the left breast? | Yes, No |
| Category | Question Template | Options |
|---|---|---|
| Mass Presence & Location | Is there a mass in the upper inner quadrant of the left breast? | Yes, No |
| Is there a mass in the upper outer quadrant of the left breast? | Yes, No | |
| Is there a mass in the lower inner quadrant of the right breast? | Yes, No | |
| Is there a mass in the central region of the breast? | Yes, No | |
| Mass Morphology | What is the shape of the mass in the left breast? | round, oval, lobular, irregular |
| What is the margin of the mass in the left breast? | circumscribed, irregular, spiculated |
| Category | Question Template | Options |
|---|---|---|
| Presence & Surgical Procedure | Is there a pathological lesion identified in the left breast? | Yes, No |
| Is there a pathological lesion identified in the right breast? | Yes, No | |
| What surgical procedure was performed on the left breast? | Lumpectomy, Mastectomy, Other | |
| What surgical procedure was performed on the right breast? | Lumpectomy, Mastectomy, Other | |
| Tumor Characteristics | Is the maximum pathological tumor size larger than 2 cm? | Yes, No |
| What is the histological grade of the tumor? | 1, 2, 3, Unknown |
| Question Template |
|---|
| Describe the overall fibroglandular tissue composition and background parenchymal enhancement of both breasts. |
| Provide a comprehensive description of the mass identified in the breast MRI. |
| Describe the imaging characteristics of the non-mass enhancement in the breast. |
| Describe the appearance of axillary and internal mammary lymph nodes. |
| Provide the final BI-RADS assessment and overall diagnostic impression. |
| Task | Fact. | Clin. | Overall | Pass (%) |
|---|---|---|---|---|
| Global background | 2.94 | 2.92 | 2.93 | 99.2 |
| Lesion localization | 2.91 | 2.89 | 2.90 | 98.6 |
| Morphology | 2.86 | 2.83 | 2.84 | 97.5 |
| Functional reasoning | 2.79 | 2.75 | 2.77 | 96.2 |
| Local invasion/nodal | 2.88 | 2.86 | 2.87 | 97.9 |
| Holistic diagnosis | 2.82 | 2.79 | 2.80 | 96.8 |
| Task Name | Exact Keys | Prefixes |
|---|---|---|
| Global Background Assessment | breast_level.breast_symmetry | breast_level.FGT., breast_level.BPE., breast_level.post_surgical_changes. |
| Lesion Detection & Localization | mass, non_mass_enhancement, non_enhancing_lesion, mass.count, non_mass_enhancement.count, non_enhancing_lesion.count | mass.location., non_mass_enhancement.location., non_enhancing_lesion.location. |
| Morphological Characterization | non_mass_enhancement.distribution, non_enhancing_lesion.lesion_type_detail | mass.size_mm., mass.morphology., non_mass_enhancement.size_mm., non_enhancing_lesion.size_mm. |
| Multi-Modal Functional Reasoning | non_mass_enhancement. internal_enhancement_pattern | mass.signal_characteristics., non_mass_enhancement.signal_characteristics., non_enhancing_lesion.signal_characteristics., mass.internal_enhancement. |
| Local Invasion & Nodal Reasoning | - | breast_level.associated_features., breast_level.lymph_nodes. |
| Holistic Diagnosis | - | breast_level.BI-RADS., breast_level.management. |
| Setting | Base VLM | GBA | LDL | Morph. | MMFR | LINR | HD | PP | Avg. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | ||
| SeVeR-3B | Qwen2.5-VL-3B | 88.90 | 99.55 | 77.78 | 99.80 | 56.89 | 97.32 | 79.56 | 99.22 | 76.85 | 97.60 | 36.02 | 97.48 | 75.47 | 99.23 | 70.21 | 98.60 |
| SeVeR-4B | Qwen3-VL-4B | 89.82 | 99.68 | 78.48 | 99.87 | 57.45 | 97.46 | 80.11 | 99.43 | 77.42 | 97.77 | 36.53 | 97.59 | 74.18 | 99.10 | 70.57 | 98.70 |
| SeVeR-8B | Qwen3-VL-8B | 91.08 | 99.74 | 80.14 | 99.90 | 59.02 | 97.68 | 81.65 | 99.55 | 79.06 | 97.96 | 38.14 | 97.87 | 75.82 | 99.24 | 72.13 | 98.85 |
| Setting | GBA | LDL | Morph. | MMFR | LINR | HD | PP | Avg. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | Acc. | BERT. | |
| Effect of (visual-affinity temperature). | ||||||||||||||||
| =0.05 | 89.10 | 99.55 | 77.64 | 99.75 | 56.72 | 97.21 | 79.42 | 99.21 | 76.83 | 97.53 | 36.05 | 97.32 | 73.26 | 98.92 | 69.86 | 98.50 |
| =0.10 † | 89.82 | 99.68 | 78.48 | 99.87 | 57.45 | 97.46 | 80.11 | 99.43 | 77.42 | 97.77 | 36.53 | 97.59 | 74.18 | 99.10 | 70.57 | 98.70 |
| =0.20 | 89.36 | 99.61 | 78.03 | 99.80 | 57.21 | 97.33 | 79.73 | 99.29 | 77.08 | 97.61 | 36.31 | 97.44 | 73.55 | 98.98 | 70.18 | 98.58 |
| Effect of (prototype budget). | ||||||||||||||||
| Type | Subtype | Multiple-choice | Free-text | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merlin | M3D-L2 | M3D-P3 | CT-CHAT | RadFM | SeVeR | Merlin | M3D-L2 | M3D-P3 | CT-CHAT | RadFM | SeVeR | ||
| 7B | 7B | 4B | 7B | 13B | 4B | 7B | 7B | 4B | 7B | 13B | 4B | ||
| Meas | Lesion Volume | 0.253 | 0.815 | 0.825 | 0.833 | 0.815 | 0.819 | 0.079 | 0.085 | 0.079 | 0.075 | 0.112 | 0.258 |
| Organ HU | 0.254 | 0.638 | 0.640 | 0.637 | 0.647 | 0.637 | 0.487 | 0.490 | 0.491 | 0.513 | 0.608 | 0.620 | |
| Organ Volume | 0.262 | 0.747 | 0.754 | 0.750 | 0.755 | 0.748 | 0.526 | 0.535 | 0.528 | 0.549 | 0.583 | 0.685 | |
| Average | 0.256 | 0.733 | 0.740 | 0.740 | 0.739 | 0.735 | 0.364 | 0.370 | 0.366 | 0.379 | 0.434 | 0.521 | |
| Metrics | E.D. | S.T.D. | L.T.D. | Medical Measurement | Image Observation | Anomaly Detection | Exposed tokens | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acc. | Acc. | Acc. | BLEU | ROUGE | BERT | BLEU | ROUGE | BERT | BLEU | ROUGE | BERT | ||
| Baseline Zs. | 3.52 | 0 | 0.15 | 0.11 | 0.08 | 76.65 | 0.26 | 0.44 | 76.22 | 0.24 | 0.54 | 76.65 | 4608 |
| SeVeR Phase1 | 22.94 | 10.54 | 21.12 | 10.47 | 20.78 | 91.23 | 4.74 | 17.94 | 86.5 | 5.36 | 17.28 | 86.24 | 512 |
| Baseline Ft. | 82.01 | 45.16 | 72.19 | 32.95 | 33.78 | 95.03 | 42.63 | 45.25 | 91.92 | 34.27 | 37.54 | 90.58 | 4608 |
| w/o CaGA | 75.73 | 41.70 | 66.66 | 30.43 | 31.19 | 87.75 | 39.36 | 41.78 | 84.88 | 31.64 | 34.66 | 83.64 | 512 |
| =256 | 82.11 | 51.36 | 75.63 | 37.21 | 39.56 | 95.95 | 48.84 | 53.72 | 93.10 | 39.07 | 44.85 | 91.56 | 256 |
| Task | Model | Acc. | BLEU | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S1 | S2 | S3 | S4 | S5 | S6 | S1 | S2 | S3 | S4 | S5 | S6 | ||
| Global Background Assessment | w/o Proto. | 89.82 | 89.82 | 83.10 | 87.78 | 79.97 | 89.43 | 95.66 | 95.90 | 72.76 | 95.43 | 96.49 | 96.63 |
| SeVeR | 89.82 | 89.82 | 89.82 | 87.78 | 80.77 | 89.82 | 96.63 | 96.63 | 96.65 | 96.63 | 96.44 | 96.63 | |
| Lesion Detection & Localization | w/o Proto. | 78.39 | 76.60 | 69.76 | 72.68 | 54.69 | 73.55 | 97.78 | 98.16 | 60.99 | 97.53 | 98.62 | 98.74 |
| SeVeR | 78.39 | 76.60 | 80.21 | 72.67 | 54.80 | 78.48 | 98.77 | 98.77 | 98.62 | 98.76 | 98.56 | 98.61 | |
| Morphological Characterization | w/o Proto. | 57.35 | 49.50 | 37.80 | 53.65 | 27.92 | 57.68 | 73.63 | 74.42 | 41.22 | 73.96 | 74.78 | 70.34 |
Medical VQA
Medical visual question answering studies how AI systems answer clinical questions using medical images and related patient or report data.
See all 175 papers